Latest Merck & Co. Stories
Pembrolizumab Demonstrated 28 Percent Overall Response Rate and 76 Percent Disease Control Rate in Difficult-to-Treat Cancer First Findings from KEYNOTE-028, Merck's Innovative
International Collaboration's initial focus is to solve 3D structures of significant drug targets for diabetes, cancer and mental disorders LOS ANGELES and SHANGHAI, Feb.
KENILWORTH, N.J., Feb.
SAN DIEGO and LEXINGTON, Mass., Dec.
The Society for Clinical Research Sites welcomes Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA as its newest Global Impact Partner ELLICOTT CITY, Md., Oct.
- Emitting flashes of light; glittering.